Sagent Pharmaceuticals (Nasdaq: SGNT) is expected to report Q2 earnings on Aug. 6. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Sagent Pharmaceuticals's revenues will expand 37.1% and EPS will remain in the red.

The average estimate for revenue is $58.5 million. On the bottom line, the average EPS estimate is -$0.02.

Revenue details
 Last quarter, Sagent Pharmaceuticals booked revenue of $60.2 million. GAAP reported sales were 57% higher than the prior-year quarter's $38.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.17. GAAP EPS were $0.34 for Q1 compared to -$0.30 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Recent performance
 For the preceding quarter, gross margin was 30.7%, much better than the prior-year quarter. Operating margin was 8.9%, much better than the prior-year quarter. Net margin was 16.3%, much better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $245.9 million. The average EPS estimate is $0.29.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 14 members out of 16 rating the stock outperform, and two members rating it underperform. Among three CAPS All-Star picks (recommendations by the highest-ranked CAPS members), one give Sagent Pharmaceuticals a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sagent Pharmaceuticals is outperform, with an average price target of $19.13.